The aim of this study was to develop an empirical approach to classifying
INTRODUCTION
Transthyretin amyloidosis (ATTR) is a progressive, degenerative disease. In familial ATTR, a single gene mutation leads to instability and dissociation of the TTR tetramer, leading to amyloid formation. Wildtype TTR can de-stabilize with advancing age and also lead to amyloid formation.
Two common sites of amyloid deposition are peripheral nerves and the heart. Typical early neuropathic symptoms are paresthesias, sensory deficit, and distal neuropathic pain with a distal-proximal progression. Deposition in the myocardium leads to diastolic dysfunction, restrictive cardiomyopathy, arrhythmias, and heart failure. Autonomic neuropathy including erectile dysfunction, bladder paresis, postural hypotension, and gastrointestinal symptoms such as nausea, constipation, and diarrhea may also occur [1, 2] .
The primarily neuropathic and cardiac phenotypes are known as transthyretin familial amyloid polyneuropathy (TTR-FAP) and transthyretin cardiomyopathy (TTR-CM), respectively. However, cardiac involvement is not uncommon in TTR-FAP, especially in later stages, and neuropathy can appear in patients with TTR-CM [3, 4] . Both groups can experience autonomic symptoms.
Attempts to classify patients based on genotype have limitations. There is significant overlap in presenting symptoms and various mutations have been classified on a ''spectrum'' ranging from predominantly neurologic to predominantly cardiac, with mixed presentations involving varying degrees of both neurologic and cardiac symptoms in between [4] . Even within the most common TTR mutation, V30M (valine is replaced by methionine at position 30), there is a tremendous heterogeneity of presentation [5, 6] . Classification by genotype has largely been focused on the distinction between the most common variant, V30M, and other mutations that are often lumped together into one non-V30M group, and the wild-type group.
Another a priori approach to classification of patients with ATTR that has been widely used classifies them into neuropathic, cardiac, and mixed (with features of both neuropathy and cardiomyopathy) groups based on their phenotypic presentation, regardless of their genotype.
Until now, little empirical research has been undertaken to develop a classification scheme for the full spectrum of patients with ATTR. In this study, we grouped patients with symptomatic ATTR based on their clinical signs and symptoms using latent class analysis (LCA) [7, 8] and explored the relationships between latent class (LC) membership and clinical measures.
METHODS

Standard Protocol Approvals,
Registrations, and Patient Consents
The Transthyretin Amyloidosis Outcomes Survey (THAOS; ClinicalTrials.gov number, NCT00628745) is a longitudinal, observational registry of symptomatic patients with ATTR (familial and wild type) and asymptomatic mutation carriers. One of its principal aims is to better understand and characterize the natural history of the disease by studying a large and heterogeneous patient population. The design and methodology of THAOS, including data collection and assessments, are described elsewhere [9] . Approval from local Ethical Review Board/Institutional Review Board was obtained, all participants provided written informed consent, and use of THAOS data for this study was approved by the THAOS Scientific Board.
Patients
This analysis included symptomatic patients participating in THAOS as of June 2013.
Patients who had liver or heart transplantation prior to enrollment were excluded.
Clinical Signs and Symptom Data
Signs and symptom data collected at THAOS enrollment were used. Individual signs and symptoms were dichotomously coded as ''present'' if assessed as possibly or definitely related to ATTR or ''absent'' if absent or deemed not related to ATTR. In total, 27 signs and symptoms reported for at least 5% of the patients were included in this study.
Other Measures
Demographic and clinical variables were examined. Patients' rating of their current health (using the sixth item, Health State, with 0 as the worst and 100 the best imaginable health state) was also analyzed.
Statistical Analysis
Latent class analysis [7, 8] is a statistical method used to find LCs (subgroups or natural taxa) using categorical data. Generally applied in social and behavioral science research, it is an extension of work pioneered in psychology that posits unobservable (latent) structures underlie observable or manifest psychological phenomena [10] [11] [12] . LCA classifies individuals into mutually exclusive LCs and assumes that all variables are independent within each LC; thus, the LC explains the associations among the observed variables (e.g., symptoms). Two As recommended, we fit an initial set of models, specifying two to six LCs, without any grouping variable or covariates [13] . The adjusted Bayesian information criteria (BIC) for the separate models were then compared (smaller is better). Measurement invariance across ATTR disease duration groups (\4 and C4 years) was tested by comparing a model in which there were free estimations of the model parameters with the same model including restrictions equating the class membership and item response probability parameters across groups.
Due to the large number of parameters estimated, each model selected the optimal set of 40 starting values to find the best parameter estimates and avoid suboptimal local maxima of the likelihood function [14] .
The software used was the LCA procedure, developed for SAS Ò by the Methodology Center, Pennsylvania State University [13, 14] .
General linear models (continuous data) and logistic regression (categorical data) were used to test the effect of LC, ATTR duration, and the interaction of the two on health status measures. A log-linear model was used to compare results for the non-ordinal groups based on a priori classification.
RESULTS
Patients
Of the 979 individuals who were symptomatic at enrollment, 971 had data on ATTR symptom duration and were included in this analysis. The mean age ± standard deviation (SD) was 53.5 ± 18.0 years. Males comprised 60% of the sample. The median ATTR duration was 3.33 years, with mean ± SD of 5.6 ± 6.7 years, and 57% had ATTR duration\4 years. Time since diagnosis was available for 608 patients with a mean ± SD of 1.8 ± 2.8 years.
Latent Class Analyses
Fit statistics were examined for two to six LC solutions by plotting the adjusted BIC as recommended by Nylund et al. [15] . The BIC improved (declined) from two to five class solutions. The four-class solution was chosen for better stability among the potential models.
Analyses assessing the impact of ATTR duration as a grouping variable on the LCA indicated that it had a significant contribution (v 2 = 338.7; df = 108; P\0.0001).
Each patient had a probability calculated for membership in each of the four LCs and was assigned to the LC with the highest probability.
The individual posterior probabilities used to categorize patients into LCs were strong, with means within LC ranging from 0.91 to 0.98 ( Table 1 ). The estimated item response probabilities for each LC grouped by ATTR duration are shown in Fig. 1 and in Table S1 in the electronic supplementary material (ESM).
LC1: Severe Neuropathy/Severe Autonomic LC1 had high probabilities of neuropathic symptoms such as pain and tingling, autonomic symptoms (both upper and lower gastrointestinal, urinary, heart involvement, and weight loss), with markedly higher probabilities among patients with ATTR duration of C4 years (Fig. 1a ). The probability of walking disability was high in both disease duration groups. This class was best described as severe neuropathy/severe autonomic. The symptom pattern was the same in both disease duration groups, but with higher frequency in those with longer disease duration (Fig. 1a ). The estimated class probabilities were 16% and 14% among those with ATTR duration of \4 and C4 years, respectively ( . 1d ). with disease duration C4 years in LC1, the prevalence was 37.0%. The difference in prevalence between disease durations was even greater for LC2: 9.8% for\4 years and 33.3% for C4 years. Differences for LC3 and LC4 were more modest, but for both groups those with longer duration had higher rates ( Table 2 ).
Comparisons of Health Status Measures by LC and ATTR Duration
In LC1 and LC2, mBMI was lower for patients with disease duration C4 years, while LC3 and LC4 showed relatively little difference between disease duration categories ( Table 2) .
Karnofsky scores for patients with longer disease duration were lower than those with shorter disease duration for each LC ( The EQ-5D-3L Index and Health Status scores in LC1 and LC2 were lower for patients with disease duration C4 years, while for LC3 and LC4 the differences were more modest (Table 3) . Generally, the responses to the EQ-5D-3L individual items for Mobility, Performance of usual activities, and Self-care indicated greater impairment across all LCs with longer disease duration ( Nearly all (98.8%) patients in LC2 with disease duration\4 years would have been classified as being neuropathic. However, with longer disease duration, there was greater variability: 75.5% would have been classified into neuropathy, 12.8% mixed, and 11.8% cardiac groups (Fig. 2a ).
Patients in LC3 would have been largely classified as having cardiomyopathy using the a priori approach, regardless of disease duration. However, among those with disease duration C4 years, 8.0% would have been classified as mixed, compared with 3.7% for patients with disease duration \4 years (Fig. 2b) .
Patients in LC4 would have been primarily classified a priori as having neuropathy in both disease duration categories (85.1% and 81.3% for\4 and C4 years duration, respectively) ( Fig. 2 ). Patients would have been classified as mixed in 9.5% and 9.8% and as having cardiomyopathy in 5.4% and 8.9% for the \4 and C4 years duration groups, respectively. Fig. 2 Comparison between the LC analysis classification and the a priori patient classification: a disease duration \4 years, b disease duration C4 years. P values for the main effects of LC, the A-Du, and the interaction of LC and A-Du were \0.0001, 0.3522, and 0.0438, respectively. ATTR transthyretin amyloidosis, A-Du ATTR disease duration group, LC latent class, LC1 severe neuropathy/severe autonomic, LC2 moderate to severe neuropathy/low to moderate autonomic involvement, LC3 severe cardiac, LC4 moderate to severe neuropathy Table 3 Patient responses to the EQ-5D-3L instrument at enrollment 
DISCUSSION
This study is the first attempt to empirically categorize a broad spectrum of patients with ATTR based on signs and symptoms using LCA.
After testing various models, we found a four-class LC solution best suited the data.
These classes were characterized by the predominant symptoms to be severe neuropathy/severe autonomic (LC1), moderate to severe neuropathy/low to moderate autonomic involvement (LC2), severe cardiac (LC3), and moderate to severe neuropathy (LC4). These groups reflected the variability in the clinical presentation of ATTR. The measures of health status varied by LC in interpretable patterns, supporting the LCA approach.
Disease duration affected the clinical presentation for the majority of patients with ATTR studied, with either a greater number of symptoms emerging as the disease progressed or an apparent increase in the frequency of the earlier symptoms over time. The exception was LC3, in which clinical presentation varied little between the disease duration groups. This analysis included many different mutations to arrive at patient groups that would encompass the entire range of ATTR. In this study, the most common mutation in the world, the V30M mutation, was found in all four LCs, mirroring the variability in symptom presentation in that single mutation [5, 6] .
Future LCA work could be done to further explore this variability as well as the impact of the age of disease onset.
This four-class LC solution offers promise in categorizing patients with ATTR across the spectrum of disease; it also offers a refinement of the a priori approach classifying patients with ATTR based on phenotype: neuropathy, cardiac, or mixed. Although there was overlap between these two classification approaches, a particular strength of the LCA solution was that it allowed for finer distinctions between patients with neuropathy and those with mixed presentation. An additional strength was that it incorporated disease duration, which is an important factor in understanding ATTR.
The LCA approach may be useful for studying ATTR disease progression over time and in examining the clinical outcome of this disease. Although this study was limited in its cross-sectional approach to disease duration, future work could include the application of longitudinal LCA to look at shifts between the LCs over time to confirm and extend the results reported here.
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